PracticeUpdate Dermatology Best of 2018

NEW

First IL-23 inhibitor with 12-weekly dosing * and results that last † * First IL-23 inhibitor approved with 12 weekly dosing after initial doses at weeks 0 and 4 1 † Of 100mg responders at week 28, 94% and 78% maintained PASI 75 or 90 respectively out to week 52 1